Providing Solutions for a Changing Healthcare Landscape
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty biopharmaceutical company that provides high quality, lower-cost solutions for patients, physicians, and healthcare organizations in various therapeutic areas, including respiratory disease, allergies and opioid overdose. The Company’s first approved product, SYMJEPI (epinephrine) Injection is an epinephrine injection pre-filled syringe product for use in the emergency treatment of anaphylaxis. Adamis is also currently developing other specialty pharmaceutical product candidates including ZIMHI™(naloxone) Injection, a naloxone injection for the potential treatment of opioid overdose; Tempol for the potential treatment of respiratory disease(COVID-19, influenza, RSV) and for the potential treatment of cancer(radiation induced dermatitis). With the rising costs of healthcare in recent years, Adamis has been focusing on creating low-cost therapeutic alternatives in large markets in order to grow its business and to make treatments more affordable for more people. Adamis will pursue the 505(b)(2) regulatory approval filings with the FDA whenever possible in order to minimize costs and shorten the time to market. With its lead pipeline product and specialty pharmaceutical pipeline, ADMP is poised to become a leader in the specialty biopharmaceutical industry.